Læknablaðið : fylgirit - 01.08.1981, Blaðsíða 70

68
endast til að taka tvær eða fleiri matskeið-
ar af lyfi sjö sinnum á dag ef hann má
vænta sama árangurs af öðru lyfi í töflu-
formi fjórum sinnum daglega.
Mælingar þær sem lýst er voru fram-
kvæmdar af Stefönu Gylfadóttur, meina-
tækni og kunna höfundar henni og yfir-
lækni rannsóknadeildarinnar Jóhanni L.
Jónassyni bestu þakkir fyrir aðstoðina.
SU'MMARY
Neutralizing capacity of antacid prepara-
tions have been shown to vary considerably.
Eleven antacid preparations commonly used in
Iceland were studied by the in vitro method
Fordtran et al. have shown to give results
comparable to in vivo methods. There was
great variation in neutralizing capacity as
shown in table 1. We also calculated the prices
of the same preparations according to their
neutralizing capacity. There is considerable
difference in prices (table 2). We conclude that
information on neutralizing capacity should be
readly available and taken into account when
therapy is prescribed and that cost of different
forms of therapy should be considered. In the
discussion we also compare cost of six weeks
therapy with three different regimes (table 3
and 4).
HEIMILDIR
1. Koster, A., Mosbeck, J.: Forbruget af anta-
cida og antikolinergika i Danmark. UGE
SKR LÆGER 1977, Mar 21; 139:710-711.
2. Green, F.W., Norton, R.A., Kaplan, M.M.:
Pharmacology and clinical use of antacids.
AM J HOSP PHARM 1975; 32:425-429.
3. Hollander, D., Harlan, J.: Antacids vs
placebos in peptic ulcer therapy. A cont-
rolled double-blind investigation. JAMA
1973 Dec 3; 226:1181-1185.
4. Peterson, W.L., Sturdevant, R.A.L., Frankl,
H.D. et al: Healing of duodenal ulcer with
an antacid regimen. N ENGL J MED 1977
Aug 18; 296:341-345.
5. Lam, S.K., Lam, K.C., Yeung, C.K., Yam,
L.Y., Wong, W.S.: Treatment of duodenal
ulcer with antacid and sulpiride. A double-
blind controlled study. GASTROENTERO-
LOGY 1979 Feb; 76:315-322.
6. Fordtran, J.S., Morawski, S.G., Richardson,
C.T.: In vivo and in vitro evaluation of
liquid antacids. N ENGL J MED 1973 May
3; 288:923-928.
7. Lyfjaverðskrá I, Reykjavík, Heilbrigðis- og
tryggingamálaráðuneytið, október 1979
(Með áorðnum breytingum).
8. Lyfjaverðskrá II, Reykjavík, Heilbrigðis-
og tryggingamálaráðuneytið, september
1980. (Gildir frá og með 1. október 1980).
9. Den danske Farmakopékommission 1963:
Bestemmelse af tykflydende væskers masse-
fylde med kassialkolbe Pharmacopoea Nor-
dica, editio Danica, Kobenhavn, Nyt Nor-
diskt Forlag Arnold Busck, 1963.
10. Clain, J.E., Maiagelada, J.R., Chadwick,
V.S., Hofmann, A.F.: Binding properities
in vitro of antacids for conjugated bile
acids. GASTROENTEROLOGY 1977; 73:556-
559.
11. Matzen, P.: Lægemiddelinformation. Anta-
cida. UGESKR LAEGER 1981 Mar 2; 143:
636-639.
12. Drake, D., Hollander, D.: Neutralizing
capacity and cost of antacids. ANN INT
MED 1981; 94:215-217.
13. Ippoliti, A.F., Sturdevant, R.A.L., Isenberg,
J.I. et al: Cimetidine versus intensive
antacid therapy for duodenal ulcer.
GASTROENTEROLOGY 1978; 74:393-395.
14. Fedeli, G., Anti, M., Rapaccini, G.L., De
Vitis, I., Butti, A., Civello, I.M.: A con-
trolled study comparing cimetidine treat-
ment to an intensive antacid regimen in the
therapy of uncomplicated duodenal ulcer.
DIG DIS CSI 1969 Oct; 24:758-762.
15. Ström, M., Gotthard, R., Bodemar, G.,
Waian, A.: Symptomatic relapse after
treatment for peptic ulcer with cimetidine
or antacid/anticholinergic. SCAND J.
GASTROENTEROL 1980; 15:914 (abstr.).